# US Fibroscan Market

> US Fibroscan market Research Report By Technology (Vibration-controlled Transient Electrography (VCTE), Controlled Attenuation Parameter (CAP), Others), By Modality (Portable, Non-Portable/Standalone), By Application (Hepatitis B or C, Non-alcoholic Fatty Liver Disease, Alcohol-related Liver Problems, Hemochromatosis, Others) and By End-user (Hospitals & Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Others) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.0%
- **2024:** $ 23.96 Billion
- **2025:** $ 25.16 Billion
- **2035:** $ 40.99 Billion
- **Key Players:** Echosens (FR), FibroScan (FR), Siemens Healthineers (DE), GE Healthcare (GB), Philips Healthcare (NL), Medtronic (US), Canon Medical Systems (JP), Hitachi Medical Systems (JP)

**Report ID:** MRFR/HC/51016-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-fibroscan-market-52776

---

## Market Summary

## **US Fibroscan market Overview**

As per MRFR analysis, the US Fibroscan Market Size was estimated at 19.55 (USD Billion) in 2024.The US Fibroscan market Industry is expected to grow from 22.85(USD Billion) in 2025 to 37 (USD Billion) by 2035. The US Fibroscan Market CAGR (growth rate) is expected to be around 4.479% during the forecast period (2025 - 2035)

**Key US Fibroscan Market Trends Highlighted**

The US Fibroscan market is experiencing notable growth driven by several key market drivers. The increasing prevalence of liver diseases, such as non-alcoholic fatty liver disease (NAFLD) and hepatitis, is pushing healthcare providers to adopt advanced diagnostic tools. Additionally, there is a growing awareness among physicians and patients about the importance of early diagnosis and monitoring of liver conditions, contributing to a higher demand for non-invasive diagnostic technologies like Fibroscan. This trend is further supported by initiatives from various public health organizations aimed at health education and outreach regarding liver health.

Opportunities for capture in the US Fibroscan market include the expansion of Fibroscan technology in rural and underserved areas, where access to specialized liver care is often limited. Moreover, the integration of Fibroscan with telemedicine platforms could enhance patient monitoring and follow-up services, thus opening new channels for patient engagement and increased testing. As insurance coverage for such diagnostic procedures evolves, patients will likely have greater access, stimulating market growth. Recent trends in the sector indicate a shift towards personalized medicine, wherein treatment plans are tailored to the unique needs of patients based on Fibroscan results.

The technology's ability to provide real-time liver stiffness measurements has positioned it as a preferred method among clinicians looking for accurate assessments without invasive procedures. Furthermore, collaborations between technology companies and healthcare providers are emerging, focused on refining and enhancing the capabilities of Fibroscan devices, ensuring they meet the clinical diagnostic needs of today.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**US Fibroscan market Drivers**

**Rising Prevalence of Liver Diseases**

The increasing incidence of liver diseases, particularly non-alcoholic fatty liver disease (NAFLD) and viral hepatitis, is a significant driver for the growth of the US Fibroscan Market Industry. According to the Centers for Disease Control and Prevention (CDC), approximately 4.5 million people in the United States have liver conditions, which have been rising by about 3% annually over the past decade. Organizations such as the American Liver Foundation play a pivotal role in raising awareness and advocating for early diagnosis and treatment of liver diseases, thereby driving demand for advanced diagnostic tools such as Fibroscan.

Healthcare practitioners are now adopting Fibroscan technology in clinical settings due to supporting guidelines from the Food and Drug Administration, which allow non-invasive approaches to liver assessment.

**Technological Advancements in Fibroscan Devices**

Innovations in Fibroscan technology, including improved accuracy and user-friendliness, are propelling the US Fibroscan Market Industry forward. Recent advancements in elastography techniques have increased the precision of liver stiffness measurements, attracting healthcare providers to adopt these devices. A report from the American Association for the Study of Liver Diseases indicates that the accuracy of Fibroscan for diagnosing significant liver fibrosis has improved to around 90% with the latest technology.
Major players in the market are continually investing in Research and Development (R&D) for these advancements, making Fibroscan a critical tool for liver health assessment in the US.

**Increasing Awareness of Preventive Healthcare**

The growing emphasis on preventive healthcare measures is significantly boosting the demand for non-invasive diagnostic tools like Fibroscan in the US Fibroscan Market Industry. Public health initiatives by organizations like the CDC emphasize the importance of early diagnosis and lifestyle modifications in preventing chronic diseases, including liver conditions. Data shows that approximately 65% of adults in the US engage in health screenings, an increase from previous years, leading to higher usage of liver assessment tools.
This rise in awareness and the adoption of preventive healthcare practices create a favorable environment for Fibroscan technology.

**Regulatory Support and Healthcare Reimbursement Policies**

Supportive regulatory frameworks and reimbursement policies for innovative medical devices positively influence the growth of the US Fibroscan Market Industry. Recent changes in Medicare reimbursement policies have expanded coverage for non-invasive liver assessment methods, making Fibroscan more accessible to a broader patient population. The increase in insurance coverage by major providers has led to a rise in patient screenings for liver diseases, demonstrating a significant increase in the adoption of this technology.
This regulatory support ensures that both healthcare providers and patients see the value in using Fibroscan for the early detection and management of liver diseases.

**US Fibroscan market Segment Insights**

**Fibroscan Market Technology Insights**

The US Fibroscan Market focuses on advanced technologies that enhance the assessment of liver health, primarily through tools based on techniques like Vibration-controlled Transient Elastography (VCTE) and Controlled Attenuation Parameter (CAP). The growth of the market is underpinned by increasing cases of liver diseases, driven by factors such as obesity and viral hepatitis. The technology segment plays a pivotal role in delivering accurate and non-invasive assessments, thus meeting the rising demand for efficient liver evaluation methods within the healthcare system.

VCTE remains significant due to its ability to provide precise measurements of liver stiffness, thereby assisting healthcare providers in diagnosing conditions like fibrosis. CAP technology is essential for measuring liver fat content, making it crucial in evaluating non-alcoholic fatty liver disease, which has become more prevalent in the United States. These innovations reflect a growing trend toward non-invasive diagnostic methods in the medical field, facilitating quicker clinical decisions and improving patient experiences. Additionally, ongoing Research and Development efforts in this area are exploring ways to combine these technologies further, enhancing their sensitivity and specificity.

The demand for advanced technologies in liver assessment presents opportunities for growth in the US Fibroscan Market, propelling forward innovations and enabling better patient management strategies. Overall, the technology segment is positioned to significantly influence the landscape of liver disease diagnosis and management in the US, emphasizing the importance of continual advancements and their integration within healthcare practices.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Fibroscan Market Modality Insights**

The US Fibroscan Market, particularly focusing on the Modality segment, is experiencing noteworthy dynamics driven by advancements in diagnostic technologies and patient care requirements. The market is primarily divided into Portable and Non-Portable/Standalone modalities, each offering distinct advantages. Portable Fibroscan devices are increasingly significant due to their flexibility, enhancing accessibility in various healthcare settings such as outpatient clinics and rural health facilities, which are vital in the vast US healthcare landscape. This adaptability fosters increased patient throughput and improves overall diagnostic efficiency.

Meanwhile, Non-Portable/Standalone devices dominate larger healthcare institutions owing to their advanced features and capabilities, making them essential for comprehensive liver assessment in specialized settings. Trends such as an increasing focus on non-invasive procedures, coupled with the need for timely liver disease diagnoses, are propelling market growth. However, challenges such as high initial costs and the requirement for trained professionals to operate sophisticated devices remain pertinent. Overall, as the awareness around liver diseases rises in the US, these modalities will likely play pivotal roles in enhancing healthcare delivery and patient outcomes.

The ongoing Research and Development in the Fibroscan Market will further support both modalities by introducing innovative technologies to meet evolving market needs.

**Fibroscan Market Application Insights**

The Application segment of the US Fibroscan Market plays a crucial role in diagnosing and managing liver diseases, serving a diverse patient demographic with various conditions. Key applications within this segment include Hepatitis B or C, which remain persistent health concerns in the US, affecting millions. Non-alcoholic Fatty Liver Disease has gained increasing attention due to rising obesity rates, making it a significant focus for the market. Also noteworthy are Alcohol-related Liver Problems, which highlight the importance of understanding lifestyle-related liver conditions in public health strategies.

Hemochromatosis, a hereditary disorder, is another vital area, emphasizing the need for targeted diagnostic technologies. Other applications encompass a variety of liver diseases, demonstrating the broad scope of the Fibroscan utility. The projected growth of this market indicates an expanding awareness of liver health, alongside improving technology, which enhances diagnosis capabilities, ultimately driving growth and innovation within the US Fibroscan Market. As healthcare providers and patients increasingly prioritize early diagnosis and treatment options, the demand for advanced fibroscan applications is expected to rise.

**Fibroscan Market End-user Insights**

The End-user segment of the US Fibroscan Market showcases a diverse landscape driven by various healthcare providers, each playing a significant role in service delivery. Hospitals and Clinics constitute a large share of this segment, offering comprehensive services and advanced diagnostic capabilities, which makes them crucial in patient management. Diagnostic Centers are also essential as they focus on specialized testing and provide timely results, catering to a growing number of patients with liver-related health issues. Additionally, Ambulatory Surgical Centers are noteworthy for their efficiency in performing outpatient procedures related to fibrotic diseases, enhancing patient convenience and reducing healthcare costs.

Other facilities encompass a range of healthcare settings, including community health clinics and private practices that contribute to accessibility and patient outreach for Fibroscan services. This segmentation reflects the increasing awareness and demand for non-invasive liver diagnostics, as well as the ongoing advancements in technology and treatment modalities that continue to shape the US Fibroscan Market dynamics. The integration of innovative solutions across these End-user categories presents substantial opportunities for growth and improves patient outcomes across the healthcare spectrum.

**US Fibroscan market Key Players and Competitive Insights**

The US Fibroscan Market has been experiencing significant growth and transformation as companies strive to meet the increasing demand for non-invasive and accurate diagnostic tools for liver diseases. The competition in this sector is marked by innovation, technological advancements, and strategic partnerships aimed at broadening market access and enhancing product offerings. With the prevalence of liver conditions on the rise, particularly non-alcoholic fatty liver disease, firms in the market are focused on improving patient outcomes through better diagnostic solutions.

This landscape is further shaped by regulatory developments, reimbursement policies, and the need for companies to adapt to evolving customer needs and healthcare trends. Fujifilm Holdings Corporation has established a robust presence in the US Fibroscan Market through its commitment to innovation and quality. The company specializes in developing advanced imaging technologies that enhance the accuracy of liver assessments. Fujifilm's strengths lie in its comprehensive research and development initiatives, which enable the company to stay ahead of market trends and deliver cutting-edge solutions.

By utilizing its extensive expertise in medical imaging, Fujifilm has successfully created FibroScan devices that are user-friendly and effective in diagnosing liver conditions. The company's focus on education and training for healthcare professionals further solidifies its reputation as a trusted leader in the US market. In the landscape of the US Fibroscan Market, Boston Scientific stands out due to its innovative approaches and a strong portfolio of diagnostic solutions. The company is recognized for providing a range of advanced medical devices tailored to the specific needs of healthcare providers in the field of gastroenterology and hepatology.

Boston Scientific's commitment to developing products that enhance patient care is evident in their offerings, which often include tools for minimally invasive procedures alongside Fibroscan technologies. Their strategic mergers and acquisitions have enabled them to expand their market presence and capabilities in liver diagnostics. Boston Scientific continually invests in research and development, which strengthens its position in the US market by allowing the company to deliver state-of-the-art solutions that align with the evolving demands of healthcare professionals and patients.

**Key Companies in the US Fibroscan Market Include**

**US Fibroscan market Industry Developments**

The US Fibroscan Market has seen notable developments recently, driven by technological advancements and increased demand for non-invasive diagnostic tools in hepatology. Companies such as Fujifilm Holdings Corporation, Echosens, and Siemens Healthineers are expanding their service portfolios to enhance liver disease diagnostics. In October 2023, it was reported that Boston Scientific entered into a strategic partnership to improve Fibroscan-related technologies, solidifying its position in the market. Additionally, there have been increased valuations for firms involved in liver health, reflecting a broader trend towards preventive healthcare.

The growing prevalence of liver-related diseases in the US, coupled with an increasing focus on early detection and intervention strategies, continues to drive market growth. Historical milestones include the 2021 FDA approval of enhanced Fibroscan devices, which significantly contributed to market penetration. While recent mergers and acquisitions specifically involving these companies have not been prominent, the landscape remains dynamic, with ongoing investments being made to advance Research and Development efforts in liver diagnostics. The intersection of innovation and a rising awareness of liver health is propelling the evolution of the US Fibroscan Market, warranting further scrutiny.

**Fibroscan Market Segmentation Insights**

## Market Drivers

### Enhanced Reimbursement Policies

The evolution of reimbursement policies in the US healthcare system is positively impacting the fibroscan market. As insurers recognize the value of non-invasive diagnostic tools, there has been a gradual shift towards covering fibroscan procedures. Improved reimbursement rates encourage healthcare providers to adopt these technologies, making them more accessible to patients. This trend is likely to stimulate market growth, as financial barriers diminish and more facilities integrate fibroscan into their diagnostic offerings. The fibroscan market may experience a notable increase in utilization rates, potentially leading to a market expansion of approximately 12% over the next few years.

### Increasing Prevalence of Liver Diseases

The rising incidence of liver diseases in the US is a crucial driver for the fibroscan market. Conditions such as non-alcoholic fatty liver disease (NAFLD) and hepatitis are becoming more common, with estimates suggesting that NAFLD affects approximately 25% of the US population. This growing prevalence necessitates effective diagnostic tools, such as fibroscan technology, to assess liver stiffness and fibrosis. As healthcare providers seek to improve patient outcomes, the demand for non-invasive diagnostic methods is likely to increase. Consequently, the fibroscan market is expected to expand as more healthcare facilities adopt these technologies to manage liver health effectively.

### Rising Demand for Preventive Healthcare

The increasing focus on preventive healthcare is driving the fibroscan market in the US. Patients and healthcare providers are becoming more proactive in managing health, particularly concerning liver health. This shift is reflected in the growing number of routine screenings and check-ups that include liver assessments. As awareness of liver diseases rises, patients are more likely to seek non-invasive testing options like fibroscan. This trend is expected to propel the market forward, as healthcare systems adapt to meet the demand for preventive measures. The fibroscan market could see a substantial increase in adoption rates, potentially reaching a 20% growth in the coming years.

### Growing Investment in Healthcare Infrastructure

Investment in healthcare infrastructure in the US is a significant driver for the fibroscan market. As hospitals and clinics upgrade their facilities and equipment, there is a growing emphasis on incorporating advanced diagnostic tools. The US healthcare system is witnessing a shift towards value-based care, which prioritizes patient outcomes and cost-effectiveness. This trend encourages healthcare providers to invest in technologies that facilitate early detection and management of liver diseases. Consequently, the fibroscan market is likely to benefit from increased funding and resources allocated to enhance diagnostic capabilities, potentially leading to a market growth rate of around 10% annually.

### Advancements in Non-Invasive Diagnostic Techniques

Technological innovations in non-invasive diagnostic methods are significantly influencing the fibroscan market. The development of advanced elastography techniques allows for more accurate assessments of liver stiffness, which is critical for diagnosing liver fibrosis. These advancements not only enhance the reliability of results but also reduce the need for invasive procedures like liver biopsies. As healthcare providers increasingly prioritize patient comfort and safety, the adoption of fibroscan technology is likely to rise. The market is projected to grow as these non-invasive techniques become more integrated into routine clinical practice, potentially leading to a market value increase of over 15% by 2027.

## Future Outlook

The [Fibroscan Market](https://www.marketresearchfuture.com/reports/fibroscan-market-21914) is projected to grow at a 5.0% CAGR from 2025 to 2035, driven by technological advancements, increasing prevalence of liver diseases, and rising healthcare expenditure.

**New opportunities:**

- Development of portable fibroscan devices for remote diagnostics.
- Partnerships with telehealth platforms to enhance service delivery.
- Expansion into emerging markets with tailored pricing strategies.

By 2035, the fibroscan market is expected to achieve substantial growth, reflecting evolving healthcare needs.

## Segment Insights

### By Technology: VCTE (Largest) vs. CAP (Fastest-Growing)

In the US fibroscan market, Vibration-controlled transient electrography (VCTE) currently dominates the technology segment, holding the largest market share. This segment is favored for its advanced capabilities in assessing liver stiffness and providing accurate diagnoses. Controlled Attenuation Parameter (CAP) is emerging as a significant player, reflecting a growing preference among clinicians for non-invasive solutions that complement VCTE. The remaining segment classified as 'Others' represents alternative technologies with niche applications, but their overall contribution remains limited compared to VCTE and CAP.

Growth trends in the technology segment are driven by increasing awareness of liver diseases, a push for non-invasive diagnostic methods, and technological advancements in fibroscan devices. The demand for reliable, efficient, and patient-friendly options fuels the growth and expansion of CAP, making it the fastest-growing segment. Continued investment in research and development further strengthens the market potential of both VCTE and CAP, ensuring sustained evolution within the US fibroscan market.

Technology: VCTE (Dominant) vs. CAP (Emerging)

Vibration-controlled transient electrography (VCTE) has established itself as the dominant technology in the US fibroscan market, known for its precision in measuring liver stiffness and providing critical data for liver health assessments. Its widespread adoption among healthcare professionals is attributed to the non-invasive nature of the procedure and its reliability. On the other hand, Controlled Attenuation Parameter (CAP) is gaining traction as an emerging technology, particularly for its effectiveness in assessing liver fat content. As healthcare providers increasingly recognize the importance of comprehensive liver diagnostics, CAP's role is expected to expand, complementing the established framework set by VCTE.

### By Modality: Portable (Largest) vs. Non-Portable/Standalone (Fastest-Growing)

In the US fibroscan market, the Portable modality has emerged as the largest segment, commanding significant market share due to its convenience and ease of use. This segment meets the needs of healthcare providers who require flexibility in patient care, allowing for on-site evaluations which have been increasingly favored in various clinical settings.

Conversely, the Non-Portable/Standalone segment is recognized as the fastest-growing within the market. This growth is driven by advancements in technology and increased adoption in hospitals where permanent installations provide enhanced features and capabilities. As healthcare facilities continue to integrate sophisticated diagnostic tools, this trend is expected to bolster the segment significantly.

Modality: Portable (Dominant) vs. Non-Portable/Standalone (Emerging)

The Portable modality dominates the market by offering significant advantages such as mobility and user-friendliness, appealing particularly to clinicians who operate in diverse environments such as rural areas and outpatient settings. Its compact design enables easy transport, making it an ideal choice for point-of-care testing. On the other hand, the Non-Portable/Standalone segment is emerging rapidly, characterized by advanced technology that allows for comprehensive testing and detailed analysis. Hospitals and specialized diagnostic centers prefer this modality due to its stability and functionality, which support higher throughput and better data management capabilities, indicating a shift towards more permanent solutions in the fibroscan landscape.

### By Application: Hepatitis B or C (Largest) vs. Nonalcoholic fatty liver disease (Fastest-Growing)

The market share distribution in the application segment of the US fibroscan market showcases a significant dominance by the Hepatitis B or C category, which holds a substantial portion of the overall market. Following this, Nonalcoholic fatty liver disease is increasingly gaining traction among healthcare providers, indicating a shift in focus towards this condition due to rising obesity rates and awareness of metabolic disorders.

Growth trends in this segment are being driven by an increase in liver disease prevalence, advancements in fibroscan technology, and a growing understanding of liver health among the population. As awareness campaigns highlight the importance of early detection and monitoring of liver diseases, segments like Nonalcoholic fatty liver disease are expected to expand rapidly, making them a focal point for future investment and research in the US fibroscan market.

Hepatitis B or C (Dominant) vs. Nonalcoholic fatty liver disease (Emerging)

Hepatitis B or C remains the dominant application in the US fibroscan market, primarily due to the prevalence of these viral infections and the urgent need for accurate liver assessment methodologies. This category benefits from established diagnostic protocols and a strong physician referral network. In contrast, Nonalcoholic fatty liver disease is emerging rapidly as a critical concern, particularly among overweight and obese populations. As healthcare professionals begin to recognize the impact of lifestyle factors on liver health, this segment is poised for explosive growth, driven by increased awareness and demand for non-invasive diagnostic tools.

### By End-User: Hospitals & Clinics (Largest) vs. Diagnostic Centers (Fastest-Growing)

In the US fibroscan market, Hospitals & Clinics currently command the largest share among the end-user segments, reflecting their crucial role in diagnostic imaging and patient management. They offer comprehensive healthcare services, which drives an increased demand for advanced diagnostic tools like fibroscan devices, leading to substantial market presence.

On the other hand, Diagnostic Centers are emerging as the fastest-growing segment in the US fibroscan market. This growth can be attributed to the rising demand for specialized services and a focus on early detection of liver diseases. The expansion of diagnostic centers enhances accessibility and efficiency, attracting more patients seeking advanced diagnostic options.

Hospitals & Clinics (Dominant) vs. Ambulatory Surgical Centers (Emerging)

Hospitals & Clinics remain the dominant players in the US fibroscan market due to their established infrastructure and comprehensive service offerings, allowing them to leverage advanced diagnostic technologies effectively. They cater to a wide range of patients and are equipped with specialized staff to perform fibroscan procedures, which solidifies their market position. Conversely, Ambulatory Surgical Centers are emerging as a viable option for patients seeking quicker and more focused diagnostic services. These centers are experiencing growth as healthcare shifts towards outpatient solutions, providing competitive services with shorter wait times, appealing to a growing segment of health-conscious patients.

## Competitive Benchmarking

The fibroscan market exhibits a dynamic competitive landscape characterized by rapid technological advancements and a growing emphasis on non-invasive diagnostic solutions. Key players such as Echosens (FR), Siemens Healthineers (DE), and GE Healthcare (GB) are at the forefront, leveraging innovation and strategic partnerships to enhance their market positions. Echosens (FR) has focused on expanding its product offerings and enhancing its FibroScan technology, which is pivotal in liver disease assessment. Siemens Healthineers (DE) emphasizes digital transformation, integrating AI capabilities into its diagnostic tools, thereby improving accuracy and efficiency. GE Healthcare (GB) is also investing in research and development to refine its imaging technologies, which collectively shapes a competitive environment that prioritizes technological superiority and patient-centric solutions.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and optimize supply chains. The market structure appears moderately fragmented, with several players vying for market share, yet dominated by a few key firms that influence pricing and innovation trends. This competitive structure fosters an environment where collaboration and strategic alliances are essential for growth and market penetration.

In October  Echosens (FR) announced a partnership with a leading healthcare provider to enhance the accessibility of its FibroScan technology across the United States. This strategic move is likely to expand its market reach and improve patient access to non-invasive liver diagnostics, aligning with the growing demand for efficient healthcare solutions. The partnership underscores Echosens' commitment to enhancing its service delivery and market presence.

In September  Siemens Healthineers (DE) launched a new AI-driven software that integrates with its existing imaging systems, aimed at improving diagnostic accuracy in liver assessments. This innovation not only positions Siemens as a leader in technological advancement but also reflects a broader trend towards the integration of AI in healthcare, which could significantly enhance patient outcomes and operational efficiencies.

In August  GE Healthcare (GB) unveiled a new initiative focused on sustainability in its manufacturing processes, aiming to reduce its carbon footprint by 30% by 2030. This initiative is indicative of a growing trend within the industry towards sustainable practices, which may resonate well with environmentally conscious consumers and healthcare providers alike.

As of November  the competitive trends in the fibroscan market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, facilitating knowledge sharing and resource optimization among key players. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, as companies strive to meet the changing demands of the healthcare landscape.

## Recent News & Developments

The US Fibroscan Market has seen notable developments recently, driven by technological advancements and increased demand for non-invasive diagnostic tools in hepatology. Companies such as Fujifilm Holdings Corporation, Echosens, and Siemens Healthineers are expanding their service portfolios to enhance liver disease diagnostics. In October 2023, it was reported that Boston Scientific entered into a strategic partnership to improve Fibroscan-related technologies, solidifying its position in the market. Additionally, there have been increased valuations for firms involved in liver health, reflecting a broader trend towards preventive healthcare.

The growing prevalence of liver-related diseases in the US, coupled with an increasing focus on early detection and intervention strategies, continues to drive market growth. Historical milestones include the 2021 FDA approval of enhanced Fibroscan devices, which significantly contributed to market penetration. While recent mergers and acquisitions specifically involving these companies have not been prominent, the landscape remains dynamic, with ongoing investments being made to advance Research and Development efforts in liver diagnostics. The intersection of innovation and a rising awareness of liver health is propelling the evolution of the US Fibroscan Market, warranting further scrutiny.

## Report Scope

| MARKET SIZE 2024 | 23.96(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 25.16(USD Billion) |
| MARKET SIZE 2035 | 40.99(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.0% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Echosens (FR), FibroScan (FR), Siemens Healthineers (DE), GE Healthcare (GB), Philips Healthcare (NL), Medtronic (US), Canon Medical Systems (JP), Hitachi Medical Systems (JP) |
| Segments Covered | Technology, Modality, Application, End-User |
| Key Market Opportunities | Advancements in non-invasive liver diagnostics drive growth in the fibroscan market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive growth in the fibroscan market, enhancing liver disease diagnostics. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US fibroscan market in 2024?**
A: The overall market valuation was $23.96 Billion in 2024.

**Q: What is the projected market size for the US fibroscan market by 2035?**
A: The projected valuation for 2035 is $40.99 Billion.

**Q: What is the expected CAGR for the US fibroscan market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during this period is 5.0%.

**Q: Which technology segments are driving the US fibroscan market?**
A: Key technology segments include Vibration-controlled transient electrography (VCTE) valued at $10.0 - $17.0 Billion and Controlled Attenuation Parameter (CAP) valued at $8.0 - $12.0 Billion.

**Q: What are the main modalities in the US fibroscan market?**
A: The market includes Portable modalities valued at $5.0 - $8.0 Billion and Non-Portable/Standalone modalities valued at $18.96 - $32.99 Billion.

**Q: Which applications are most prevalent in the US fibroscan market?**
A: Prominent applications include Hepatitis B or C valued at $9.58 - $16.38 Billion and Nonalcoholic fatty liver disease valued at $6.78 - $11.63 Billion.

**Q: What are the key end-user segments in the US fibroscan market?**
A: End-user segments include Hospitals & Clinics valued at $9.58 - $16.25 Billion and Diagnostic Centers valued at $6.78 - $11.56 Billion.

**Q: Who are the leading players in the US fibroscan market?**
A: Key players include Echosens, Siemens Healthineers, GE Healthcare, and Medtronic.

**Q: What is the growth outlook for the US fibroscan market?**
A: The market appears poised for growth, with a projected increase to $40.99 Billion by 2035.

**Q: How does the US fibroscan market compare to other regions?**
A: While specific regional comparisons are not provided, the US market shows robust growth potential, particularly in technology and application segments.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-fibroscan-market-52776*